series-b
Stage
2018
Founded
3
Investors
About
Wugen is a clinical-stage biotechnology company developing off-the-shelf CAR-T and NK cell therapies for the treatment of various cancers, including T-cell acute lymphoblastic leukemia and lymphoma.
Explore Wugen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.